0001722964 2024-06-30 0001722964 2025-04-25 0001722964 2024-01-01 2024-12-31 shares iso4217:USD 0001722964 FY false 10-K/A true 2024-12-31 --12-31 2024 false 001-38650 Y-mAbs Therapeutics, Inc. DE 86-2083865 202 Carnegie Center Suite 301 Princeton NJ 08540 646 885-8505 Common Stock YMAB NASDAQ No No Yes Yes Non-accelerated Filer true false false false false 450000000 45276915 true <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our Board of Directors, on the recommendation of our Compensation Committee, has adopted an equity granting policy (the “Equity Granting Policy”). The Equity Granting Policy provides that annual equity grants to our executive officers and employees will be approved by our Compensation Committee in January, that equity awards to our non-employee directors will be made in accordance with our Amended and Restated Non-Employee Director Compensation Policy and that equity awards to newly hired employees will be made in March, June, September and December. Under the Equity Granting Policy authority is delegated to our Chief Executive Officer to approve equity awards to newly hired employees who are not officers subject to Section 16 of the Exchange Act, subject to the parameters set forth in the policy. The Equity Granting Policy further provides that awards to newly hired employees who are officers subject to Section 16 of the Exchange Act, other than the Chief Executive Officer, must be approved by our Compensation Committee and that awards to a newly hired Chief Executive Officer must be approved by our Board upon the recommendation of our Compensation Committee. Our Compensation Committee generally does not take material nonpublic information into account when determining the timing and terms of such awards. In 2024, our Compensation Committee did not time the disclosure of material nonpublic information for the purpose of benefiting the value of executive compensation.</p> Our Board of Directors, on the recommendation of our Compensation Committee, has adopted an equity granting policy (the “Equity Granting Policy”). The Equity Granting Policy provides that annual equity grants to our executive officers and employees will be approved by our Compensation Committee in January, that equity awards to our non-employee directors will be made in accordance with our Amended and Restated Non-Employee Director Compensation Policy and that equity awards to newly hired employees will be made in March, June, September and December. true Our Compensation Committee generally does not take material nonpublic information into account when determining the timing and terms of such awards. In 2024, our Compensation Committee did not time the disclosure of material nonpublic information for the purpose of benefiting the value of executive compensation. false false